More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-UT-1: Human Uterine Leiomyosarcoma Cell Line

SK1980-537

Description

SK-UT-1 is a human uterine leiomyosarcoma cell line that grows in adherent culture. This cell line has little or no phosphorylated retinoblastoma protein compared to the SK-UT-1B cells. SK-UT-1 cells are capable of forming tumors when inoculated in immunocompromised mice.

Source

This cell line was established in 1972 from a 75-year-old Caucasian female with a uterine mixed mesodermal tumor consistent with leiomyosarcoma grade III.

Inventors

  • Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
  • Germaine Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (Pubmed ID: 327080)
  • Ganiatsas S et al. (2001) A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Oncogene 20: 3641-50 (PubMed ID:  11439327)
  • Li B et al. (2013) Curcumin induces cross-regulation between autophagy and apoptosis in uterine leiomyosarcoma cells. International Journal of Gynecological Cancer 23: 803-808 (PubMed ID: 23532091)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

  • For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org

Stage of Development

Ready to use

Indications